InvestorsHub Logo
Followers 864
Posts 27574
Boards Moderated 1
Alias Born 11/05/2010

Re: qwertytrader post# 4983

Thursday, 10/11/2012 7:46:00 AM

Thursday, October 11, 2012 7:46:00 AM

Post# of 5074
Intercept Pharmaceuticals Announces Pricing of Initial Public Offering
http://finance.yahoo.com/news/intercept-pharmaceuticals-announces-pricing-initial-110000777.html

NEW YORK, Oct. 11, 2012 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc., a clinical stage biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat chronic liver diseases, today announced the pricing of its initial public offering of 5,000,000 shares of common stock at a public offering price of $15.00 per share, before underwriting discounts. All of the common stock is being offered by Intercept. In addition, the underwriters have a 30-day option to purchase up to an additional 750,000 shares of common stock from Intercept. The Company's shares are expected to begin trading on The NASDAQ Global Market on Thursday, October 11, 2012 under the trading symbol (ICPTF).


BofA Merrill Lynch is acting as sole book-running manager for the offering. BMO Capital Markets is acting as lead manager and Needham & Company, LLC, Wedbush PacGrow Life Sciences and ThinkEquity LLC are acting as co-managers.

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.